BROADCASTS.com

b'

Healthcare analysts Arthur Wong and Adam Dibe discuss their quick thoughts on Brexit and what it means for U.S. rated pharma companies. No rating changes at this time, but some concerns on what Brexit may mean for product approval times and research funding.